GLP-1 Receptor Agonist Use Among Adults With Diabetes and Cancer History

This cross-sectional study examines how use of glucagon-like peptide-1 (GLP-1) receptor agonists varies among US adults with diabetes with or without a history of cancer.

Corresponding Author: Bismarck C. Odei, MD, Department of Radiation Oncology, Huntsman Cancer Institute, University of Utah Health, 1950 Circle of Hope Dr, Room 1570, Salt Lake City, UT 84112 (bismarck.odei@hci.utah.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.